643 related articles for article (PubMed ID: 25203869)
41. Active screening of COVID-19-associated pulmonary aspergillosis with serum beta-glucan and endotracheal aspirates galactomannan and fungal culture.
Pavone P; Russello G; Salati G; Corsini R; Salsi P; Vizzini L; Lombardini C; Spaggiari L; Besutti G; Menozzi V; Spadoni A; Facciolongo N; Piro R; Carretto E; Massari M
Mycoses; 2023 Mar; 66(3):219-225. PubMed ID: 36380646
[TBL] [Abstract][Full Text] [Related]
42. Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients.
Bhimji A; Bhaskaran A; Singer LG; Kumar D; Humar A; Pavan R; Lipton J; Kuruvilla J; Schuh A; Yee K; Minden MD; Schimmer A; Rotstein C; Keshavjee S; Mazzulli T; Husain S
Clin Microbiol Infect; 2018 Jun; 24(6):640-645. PubMed ID: 28970160
[TBL] [Abstract][Full Text] [Related]
43. [The performance of (1, 3)-beta-D-glucan and Aspergillus galactomannan measurement for early diagnosis of invasive aspergillosis in patients with hematological diseases].
Horiguchi Y
Kansenshogaku Zasshi; 2004 Jul; 78(7):566-73. PubMed ID: 15359888
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of galactomannan and beta-d-glucan assays for the diagnosis of invasive aspergillosis in clinically suspected cases.
Sarwar M; Gardezi SAH; Zaman G; Ikram A; Satti L; Khadim MT
J Pak Med Assoc; 2020 Mar; 70(3):442-446. PubMed ID: 32207422
[TBL] [Abstract][Full Text] [Related]
45. Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies.
Luong ML; Filion C; Labbé AC; Roy J; Pépin J; Cadrin-Tourigny J; Carignan S; Sheppard DC; Laverdière M
Diagn Microbiol Infect Dis; 2010 Oct; 68(2):132-9. PubMed ID: 20846585
[TBL] [Abstract][Full Text] [Related]
46. Clinical characteristics, radiologic findings, risk factors and outcomes of serum galactomannan-negative invasive pulmonary aspergillosis.
Jung J; Kim MY; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH
J Microbiol Immunol Infect; 2018 Dec; 51(6):802-809. PubMed ID: 28712819
[TBL] [Abstract][Full Text] [Related]
47. Direct comparison of galactomannan performance in concurrent serum and bronchoalveolar lavage samples in immunocompromised patients at risk for invasive pulmonary aspergillosis.
Boch T; Buchheidt D; Spiess B; Miethke T; Hofmann WK; Reinwald M
Mycoses; 2016 Feb; 59(2):80-5. PubMed ID: 26627577
[TBL] [Abstract][Full Text] [Related]
48. Use of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan.
Mikulska M; Furfaro E; De Carolis E; Drago E; Pulzato I; Borghesi ML; Zappulo E; Raiola AM; Grazia CD; Del Bono V; Cittadini G; Angelucci E; Sanguinetti M; Viscoli C
Med Mycol; 2019 Nov; 57(8):987-996. PubMed ID: 30753590
[TBL] [Abstract][Full Text] [Related]
49. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study.
Boch T; Spiess B; Cornely OA; Vehreschild JJ; Rath PM; Steinmann J; Heinz WJ; Hahn J; Krause SW; Kiehl MG; Egerer G; Liebregts T; Koldehoff M; Klein M; Nolte F; Mueller MC; Merker N; Will S; Mossner M; Popp H; Hofmann WK; Reinwald M; Buchheidt D
Clin Microbiol Infect; 2016 Oct; 22(10):862-868. PubMed ID: 27393123
[TBL] [Abstract][Full Text] [Related]
50. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients.
Hoenigl M; Koidl C; Duettmann W; Seeber K; Wagner J; Buzina W; Wölfler A; Raggam RB; Thornton CR; Krause R
J Infect; 2012 Dec; 65(6):588-91. PubMed ID: 23078908
[No Abstract] [Full Text] [Related]
51. Performance of the Euroimmun Aspergillus Antigen ELISA for the Diagnosis of Invasive Pulmonary Aspergillosis in Bronchoalveolar Lavage Fluid.
Egger M; Penziner S; Dichtl K; Gornicec M; Kriegl L; Krause R; Khong E; Mehta S; Vargas M; Gianella S; Porrachia M; Jenks JD; Venkataraman I; Hoenigl M
J Clin Microbiol; 2022 Apr; 60(4):e0021522. PubMed ID: 35350844
[TBL] [Abstract][Full Text] [Related]
52. Clinical evaluation of the newly formatted lateral-flow device for invasive pulmonary aspergillosis.
Hoenigl M; Eigl S; Heldt S; Duettmann W; Thornton C; Prattes J
Mycoses; 2018 Jan; 61(1):40-43. PubMed ID: 28922489
[TBL] [Abstract][Full Text] [Related]
53. Impact of bronchoalveolar lavage galactomannan on the outcome of patients at risk for invasive pulmonary aspergillosis.
Danpornprasert P; Foongladda S; Tscheikuna J
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S86-93. PubMed ID: 20364562
[TBL] [Abstract][Full Text] [Related]
54. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis in solid organ transplant patients: a semiprospective multicenter study.
Willinger B; Lackner M; Lass-Flörl C; Prattes J; Posch V; Selitsch B; Eschertzhuber S; Hönigl K; Koidl C; Sereinigg M; Raggam RB; Thornton CR; Krause R; Hoenigl M
Transplantation; 2014 Oct; 98(8):898-902. PubMed ID: 24879383
[TBL] [Abstract][Full Text] [Related]
55. Impact of revised EORTC/MSGERC 2020 criteria on diagnosis and prognosis of invasive pulmonary aspergillosis in patients with hematological malignancies undergoing bronchoscopy.
Acet-Öztürk NA; Ömer-Topçu D; Vurat-Acar K; Aydın-Güçlü Ö; Pınar İE; Demirdöğen E; Görek-Dilektaşlı A; Kazak E; Özkocaman V; Ursavas A; Akalın H; Özkalemkaş F; Ener B; Ali R
J Mycol Med; 2022 Nov; 32(4):101304. PubMed ID: 35738036
[TBL] [Abstract][Full Text] [Related]
56. Galactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematology patients.
Hsu LY; Ding Y; Phua J; Koh LP; Chan DS; Khoo KL; Tambyah PA
BMC Infect Dis; 2010 Mar; 10():44. PubMed ID: 20199673
[TBL] [Abstract][Full Text] [Related]
57. Comparison of different lateral flow assays on bronchoalveolar lavage fluid for invasive aspergillosis screening in non-hematological patients.
Devillers E; Scherer E; Navellou JC; Grenouillet F; Millon L; Bellanger AP
J Mycol Med; 2024 Jun; 34(2):101481. PubMed ID: 38718721
[TBL] [Abstract][Full Text] [Related]
58. Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1→3)-β-D-glucan in experimental invasive pulmonary aspergillosis.
Petraitiene R; Petraitis V; Bacher JD; Finkelman MA; Walsh TJ
Med Mycol; 2015 Aug; 53(6):558-68. PubMed ID: 26129890
[TBL] [Abstract][Full Text] [Related]
59. Combining standard clinical methods with PCR showed improved diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies and prolonged neutropenia.
Paholcsek M; Fidler G; Konya J; Rejto L; Mehes G; Bukta E; Loeffler J; Biro S
BMC Infect Dis; 2015 Jul; 15():251. PubMed ID: 26126706
[TBL] [Abstract][Full Text] [Related]
60. Aspergillus Lateral Flow Assay with Digital Reader for the Diagnosis of COVID-19-Associated Pulmonary Aspergillosis (CAPA): a Multicenter Study.
Autier B; Prattes J; White PL; Valerio M; Machado M; Price J; Egger M; Gangneux JP; Hoenigl M
J Clin Microbiol; 2022 Jan; 60(1):e0168921. PubMed ID: 34643415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
